罗夫卢米拉斯特用于贝赫特病的口腔和复发性口腔口腔炎的治疗
Kyung Bae Chung1, Hae June Sung1, Eun Hye Kim1
1Department of Dermatology, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
The Journal of dermatology
|September 23, 2025
概括
低剂量的roflumilast有效地治疗了Behçet的耐火性口腔.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 贝塞特病 (BD) 中的口腔口腔和复发性口腔口腔炎 (RAS) 引起显著的不适,特别是当标准治疗,如素或阿扎西奥普林是无效的.
- 作为一种基化酶-4 (PDE4) 抑制剂的罗夫米拉斯 (Roflumilast) 对耐火性口腔 (OU) 具有潜在的治疗选择,特别是在无法使用阿普雷米拉斯 (Apremilast) 的地区.
研究的目的:
- 调查低剂量罗米拉斯的疗效和安全性,用于治疗BD和RAS患者的耐火性OU.
- 评估罗夫卢米拉斯特在改善客观临床症状和患者报告的主观症状方面的有效性.
主要方法:
- 一个单中心,单臂,回顾性观察性研究,涉及46名耐火性OUS患者.
- 患者每天接受低剂量罗米拉斯 (0.25毫克),不良反应可能减少剂量至0.125毫克.
- 治疗结果在12周内进行评估,评估临床医生评估的反应类别和患者报告的症状,并监测不良事件.
主要成果:
- 在12周后,71.7%的患者对罗夫卢米拉斯特产生了积极反应,30.4%的患者实现了完全缓解.
- 76.1%的患者报告了不良事件,主要是胃肠道 (71.7%) 和神经系统 (17.4%) 的症状.
- 尽管经常发生副作用,但78.3%的患者可以耐受无需停止使用罗米拉斯,而15.2%的患者需要降低剂量.
结论:
- 低剂量罗米拉斯特在减少BD和RAS患者的OU方面显示出快速和持续的有效性.
- 虽然经常发生,但不良事件通常是可以管理的,这表明罗米拉斯作为一种可行的替代治疗方法.
- 进一步的研究是有必要的,以证实这些发现,考虑到研究的回顾性质和小样本大小.
更多相关视频
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
463
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
463
Peptic Ulcer Disease IV: Management
439
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
439
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
439
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
439
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.4K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
Inflammatory Bowel Disease IV: Pharmacological Management
528
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
528


